摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

dimethylcarbamic acid 3-(3-(methylaminosulfonyl)aminobenzyl)-4-methyl-2-oxo-2H-pyrano[2,3-b]pyridin-7-yl ester | 946128-73-0

中文名称
——
中文别名
——
英文名称
dimethylcarbamic acid 3-(3-(methylaminosulfonyl)aminobenzyl)-4-methyl-2-oxo-2H-pyrano[2,3-b]pyridin-7-yl ester
英文别名
dimethyl-carbamic acid 3-[3-(N-methylsulfamoylamino)benzyl]-4-methyl-2-oxo-2H-pyrano[2,3-b]pyridin-7-yl ester;[4-methyl-3-[[3-(methylsulfamoylamino)phenyl]methyl]-2-oxopyrano[2,3-b]pyridin-7-yl] N,N-dimethylcarbamate
dimethylcarbamic acid 3-(3-(methylaminosulfonyl)aminobenzyl)-4-methyl-2-oxo-2H-pyrano[2,3-b]pyridin-7-yl ester化学式
CAS
946128-73-0
化学式
C20H22N4O6S
mdl
——
分子量
446.484
InChiKey
FDHUCQKHMHMPAC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    31
  • 可旋转键数:
    7
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    135
  • 氢给体数:
    2
  • 氢受体数:
    9

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    2,6-二羟基吡啶 在 tin(II) chloride dihdyrate 、 zinc trifluoromethanesulfonate 、 sodium hydride 、 三乙胺 作用下, 以 甲醇乙酸乙酯N,N-二甲基甲酰胺乙腈 、 mineral oil 为溶剂, 反应 38.75h, 生成 dimethylcarbamic acid 3-(3-(methylaminosulfonyl)aminobenzyl)-4-methyl-2-oxo-2H-pyrano[2,3-b]pyridin-7-yl ester
    参考文献:
    名称:
    Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning
    摘要:
    Substituting a carbon atom with a nitrogen atom (nitrogen substitution) on an aromatic ring in our leads 1 la and 13g by applying nitrogen scanning afforded a set of compounds that improved not only the solubility but also the metabolic stability. The impact after nitrogen substitution on interactions between a derivative and its on- and off-target proteins (Raf/MEK, CYPs, and hERG channel) was also detected, most of them contributing to weaker interactions. After identifying the positions that kept inhibitory activity on HCT116 cell growth and Raf/MEK, compound I (CH5126766/RO5126766) was selected as a clinical compound. A phase I clinical trial is ongoing for solid cancers.
    DOI:
    10.1021/ml400379x
点击查看最新优质反应信息

文献信息

  • Novel Coumarin Derivative Having Antitumor Activity
    申请人:Iikura Hitoshi
    公开号:US20110092700A1
    公开(公告)日:2011-04-21
    The present invention provides a compound represented by general formula (1) below or a pharmaceutically acceptable salt thereof: wherein: X is selected from heteroaryl etc., Y 1 and Y 2 are selected from —N═ etc., Y 3 and Y 4 are selected from —CH═ etc., A is selected from sulfamide etc., R 1 is selected from hydrogen etc., and R 2 is selected from C 1-6 alkyl etc. The compound or salt has sufficiently high antitumor activity, and is useful in the treatment of cell proliferative disorders, particularly cancers. The present invention also provides a pharmaceutical composition containing the compound or salt as an active ingredient.
    本发明提供一种由下式(1)或其药学上可接受的盐所表示的化合物:其中,X选自杂环芳基等;Y1和Y2选自—N═等;Y3和Y4选自—CH═等;A选自磺酰胺等;R1选自氢等;R2选自C1-6烷基等。该化合物或盐具有足够高的抗肿瘤活性,并可用于治疗细胞增殖性疾病,特别是癌症。本发明还提供一种含有该化合物或盐作为活性成分的制药组合物。
  • p27 Protein Inducer
    申请人:Sakai Toshiyuki
    公开号:US20110009398A1
    公开(公告)日:2011-01-13
    The present invention provides a p27 protein inducing agent comprising a compound represented by general formula (11) below or pharmaceutically acceptable salt thereof as an active ingredient: wherein G 1 , G 2 , G 3 and G 8 are each independently selected from —N═ etc., Ring G 6 is selected from divalent aryl etc., A is selected from amino etc., G 4 is selected from oxygen etc., G 5 is selected from oxygen etc., G 7 is selected from —CH 2 — etc., and R 2 is selected from C 1-6 alkyl etc.
    本发明提供了一种p27蛋白诱导剂,其包含以下通式(11)所表示的化合物或其药学上可接受的盐作为活性成分:其中G1,G2,G3和G8各自独立地选择自—N═等,环G6选择自双价芳基等,A选择自氨基等,G4选择自氧等,G5选择自氧等,G7选择自—CH2—等,R2选择自C1-6烷基等。
  • p27 PROTEIN INDUCER
    申请人:Chugai Seiyaku Kabushiki Kaisha
    公开号:EP2172198B1
    公开(公告)日:2014-04-16
  • NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY
    申请人:CHUGAI SEIYAKU KABUSHIKI KAISHA
    公开号:EP1982982B1
    公开(公告)日:2012-09-26
  • EP1982982A1
    申请人:——
    公开号:EP1982982A1
    公开(公告)日:2008-10-22
查看更多

同类化合物

龙胆胺 龙胆定碱 西藏龙胆碱 萤光红BK 苯酰胺,N-(1,5,7,8-四氢-4-羰基-4H-吡喃并[4,3-b]吡啶-3-基)- 秦艽碱丙 秦艽甲素 盐酸伊立替康杂质20 溶剂红197 伊立替康杂质29 α.-D-核-七吡喃糖苷-6-酮糖,甲基3,7-二脱氧-2-O-甲基-4-O-(苯基甲基)- N-(3,4-二氢-2H-吡喃并[3,2-b]吡啶-4-基)-n-甲基甘氨酸 N-(2-(4-甲氧苯基)乙烯基)-吡咯烷-2,5-二酮 8-碘-3,4-二氢-2H-吡喃并[3,2-c]吡啶 7H-噻喃并[2,3-d]嘧啶 7-溴-2H-吡喃并[3,2-b]吡啶 7-氯-3,4-二氢-2H-吡喃并[2,3-B]吡啶 7-乙基-10-羟基喜树碱中间体 7,8-二氢-6H-硫代吡喃并[3,2-d]嘧啶-2,4-二醇 7,8-二氢-5H-吡喃并[4,3-b]吡啶-3-胺 7,8-二氢-2-(甲硫基)-3H-噻喃并[3,2-d]嘧啶-4(6H)-酮 6H-噻喃并[3,2-d]嘧啶 6-碘-3,4-二氢-2h-吡喃并[3,2-b]吡啶-8-甲醛 6-甲基-3,4-二氢吡喃并[4,3-d]吡啶-1-酮 6-溴-2-苯基-2H-吡喃并[2,3-b]吡啶 6-溴-2-(4-甲基苯基)-3,4-二氢-2H-吡喃并[2,3-b]吡啶 6-溴-2-(3,4-二氯苯基)-3,4-二氢-2H-吡喃并[2,3-b]吡啶 6-氯-2-(4-氯苯基)-3,4-二氢-2H-吡喃并[2,3-b]吡啶 6-氯-2-(3,4-二氯苯基)-3,4-二氢-2H-吡喃并[2,3-b]吡啶 6-(4,4,5,5-四甲基-1,3,2-二氧杂硼硼烷-2-基)-3,4-二氢-2H-吡喃[2,3-b]吡啶 6,8-二碘-3,4-二氢-2H-吡喃[3,2-b]吡啶 5H-噻喃并[2,3-d]嘧啶 5-氧杂-10-氮杂三环[6.2.1.04,9]十一碳-1,3,7,9-四烯 5,8-二氢-6H-吡喃并[3,4-b]吡啶 4H-吡喃并[2,3-b]吡啶-4-酮,6-氯-2,3-二氢-2-甲基-,(R)- 4H-吡喃并[2,3-b]吡啶-4-酮 4-羟甲基-3,4-二氢-2H-吡喃[3,2-B]吡啶-4-醇 4-甲基-7-吗啉基-2H-吡喃并[2,3-b]吡啶-2-酮 4-乙基-7,8-二氢-4-羟基-1H-吡喃并[3,4-f]吲嗪-3,6,10(4H)-三酮 4,4',5'-三甲基氮杂补骨脂素 4'-乙基-7',8'-二氢-螺[1,3-二氧戊环-2,6'(3'H)-[1H]吡喃并[3,4-f]吲哚嗪]-3',10'(4′H)-二酮-d5 4'-乙基-7',8'-二氢-4'-羟基-螺[1,3-二氧戊环-2,6'(3'H)-[1H]吡喃并[3,4-f]吲哚嗪]-3′,10′(4′H)-二酮-d5 3-异噻唑甲酰胺,N-(4-氯-7,8-二氢-5H-吡喃并[4,3-b]吡啶-3-基)- 3-(二烯丙基氨基)-7-氧代-7H-苯并吡喃并[3',2':3,4]吡啶并[1,2-a]苯并咪唑-6-甲腈 3-(4-羟苯在)-4H-吡喃[2,3-B]吡啶-4-酮 3,4-二氢-4-亚甲基-(9ci)-2H-吡喃并[3,2-b]吡啶 3,4-二氢-2h-吡喃并[3,2-b]吡啶-8-羧酸 3,4-二氢-2H-吡喃并[3,2-c]吡啶 3,4-二氢-2H-吡喃并[3,2-b]吡啶-3-基甲醇 3,4-二氢-2H-吡喃并[3,2-b]吡啶-2-醇